Table-2.

Clinicopathologic characteristics and p53 expression

	p53 expression
	0% n: 40	1 – 25% n: 41	26 – 75% n: 33	76 – 100% n: 29	P
Gender, n (%)
Male	21 (52.5%)	23 (46.9%)	15 (60.0%)	12 (41.4%)	0.5441
Female	19 (47.5%)	26 (53.1%)	10 (40.0%)	17 (58.6%)
Age, median (range) (years)	1.5 (0.2 – 11.5)	2.1 (0 – 19.6)	2.9 (1.5 – 15.3)	3.1 (0 – 7.7)	0.0033
Procedure performed for initial diagnosis, n (%)
Thoracoscopy/Thoracotomy	27 (67.5%)	29 (70.7%)	19 (57.6%)	15 (51.7%)	0.0081
Needle biopsy	2 (5.0%)	2 (4.9)	8 (24.2%)	10 (34.5%)
Unknown	11 (27.5%)	10 (24.4%)	6 (18.2%)	4 (13.8%)
Pneumothorax at time of presentation, n (%)
Yes	6 (15.0%)	9 (21.9%)	7 (21.2%)	8 (27.6%)	0.0577
No	28 (70.0%)	17 (41.5%)	13 (39.4%)	10 (34.5%)
Unknown	6 (15.0%)	15 (36.6%)	13 (39.4%)	11 (37.9%)
Neoadjuvant therapy, n (%)
Yes	7 (17.5%)	6 (14.6%)	10 (30.3%)	17 (58.6%)	0.0009
No	33 (82.5%)	34 (82.9%)	21 (63.6%)	11 (37.9%)
Unknown	0	1 (2.4%)	2 (6.1%)	1 (3.5%)
Margin status for primary surgical resection, n (%)
Positive	8 (20.0%)	14 (34.2%)	18 (54.6%)	21 (72.4%)	0.0008
Negative	20 (50.0%)	17 (41.5%)	9 (27.3%)	3 (10.3%)
Unknown	12 (30.0%)	10 (34.4%)	6 (18.2%)	5 (17.2%)
Pleuropulmonary blastoma histologic type, n (%)
Ir	15 (37.5%)	5 (12.2%)	0	0	< 0.0001
I	15 (37.5%)	18 (43.9%)	0	0
II	4 (10.0%)	11 (26.8%)	20 (60.6%)	11 (37.9%)
III	6 (15.0%)	7 (17.1%)	13 (39.4%)	18 (62.1%)
Anaplasia, n (%)
Yes	9 (22.5%)	9 (22.0%)	15 (45.5%)	25 (86.2%)	< 0.0001
No	31 (77.5%)	32 (78.1%)	18 (54.6%)	4 (13.8%)
Metastatic disease at time of presentation, n (%)
Yes	0	1 (2.4%)	3 (9.1%)	3 (10.7%)	0.1199
No	40 (100%)	40 (97.6%)	30 (90.9%)	25 (89.3%)

^*Percentages might not add to 100% due to rounding